Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

RedLips Beyond ROS: Red-Light Photocatalytic Liposomes for Hypoxia-Resistant Cancer Therapy

Coordinator
Universitat De Barcelona, Spain
Runs
1 February 2027 to 31 January 2029
Status
Running
EU funding
€194k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101273650

What the project is doing

In the project's own words, from its summary on CORDIS.

Light-activated strategies have transformed medicine, yet current approaches face major limitations. Photodynamic therapy (PDT) depends on oxygen to generate reactive oxygen species (ROS), restricting efficacy in hypoxic tumors. Photoactivated chemotherapy (PACT) releases active drugs upon irradiation but is non-catalytic, preventing sustained reactivity. A promising alternative is bioorthogonal photocatalysis, where light-driven catalysts perform specific, non-natural transformations catalytically in biological systems.

Using porphyrins, widely implemented in PDT, we will repurpose them as photocatalysts for the first catalytic strategy to generate therapeutic alkyl radicals in situ, highly cytotoxic species already shown to be effective against cancer but so far limited to prodrugs requiring enzymatic cleavage. Because enzyme activity varies and is often low in tumors, this strategy lacks robustness. By contrast, red-light activated porphyrins can trigger radical formation independently of enzymes, offering a powerful, catlytic, oxygen-independent therapeutic pathway.

Red-light-absorbing porphyrins are particularly suited for biological use, operating via single electron transfer (SET) under mild conditions and activating precursors such as Hantzsch esters and Katritzky salts, already validated for their biocompatibility. To overcome solubility and stability challenges, we will pioneer RedLips: red-light-activated photocatalytic liposomes. Liposomes, clinically proven nanocarriers, can encapsulate or embed porphyrins while maintaining catalytic activity, enabling radical formation directly in aqueous and cellular environments.

RedLips thus represent the first catalytic nanoplatform designed to produce alkyl radicals beyond ROS in situ, with spatial and temporal control. This project pioneers a new therapeutic paradigm: catalytic, oxygen-independent radical nanotherapy, pushing light-driven cancer treatment beyond the current state of the art.

Topics

Who is involved

OrganisationCityCountryRole
Universitat De BarcelonaBarcelonaSpainCoordinator
Consiglio Nazionale Delle RicercheRomaItalyAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI